Underground Biohacking
Metabolic

Semaglutide

Chris Hallewell, founder of Underground Biohacking

By , Founder, Underground Biohacking

Last reviewed

Prescription only

Semaglutide is different from most compounds on this site. It is an approved prescription medicine, backed by large randomised human trials. Those trials show major weight loss, better blood sugar, fewer heart attacks and strokes, and slower kidney decline. The evidence grade here is human, not animal. It also carries real risks: gut side effects are common, gallbladder problems are less common but serious, and the weight returns once treatment stops. Only the approved products carry the evidence described here.

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases when you eat. It tells the pancreas to release insulin, slows how fast the stomach empties, and signals the brain that you have had enough food. Your own GLP-1 breaks down within minutes. Semaglutide is a redesigned copy of that hormone. Two amino acids were swapped so the enzyme that destroys natural GLP-1 cannot get a grip. A fatty acid chain was then attached. That chain lets the molecule bind to albumin, a carrier protein in blood. Bound to albumin, it clears slowly, so one injection keeps working for days rather than minutes. This is where semaglutide parts company with the research peptides. It went through full phase 3 trials in tens of thousands of people, and it is an approved prescription medicine. It is sold as Ozempic and Rybelsus for type 2 diabetes, and as Wegovy for weight management and for lowering cardiovascular risk. Same molecule, different approved uses.

What is Semaglutide prescribed for?

  • In adults with overweight or obesity, weekly semaglutide plus lifestyle support cut body weight far more than placebo over 68 weeks.[1]Human study
  • In people with existing heart disease and obesity but no diabetes, it lowered the rate of cardiovascular death, heart attack and stroke.[2]Human study
  • In people with type 2 diabetes and chronic kidney disease, it lowered the risk of serious kidney events and of cardiovascular death.[4]Human study
  • In a head to head trial in people with type 2 diabetes, it beat dulaglutide, another GLP-1 drug, on both blood sugar and body weight.[6]Human study
  • In people with obesity and heart failure with preserved ejection fraction, it improved symptoms, physical limits and exercise capacity.[5]Human study
  • In people with obesity and moderate knee osteoarthritis, it reduced knee pain more than placebo alongside the weight loss.[7]Human study
  • In rats and mice, it changed food preference and cut food intake without slowing the rate at which energy was burned.[10]Animal or lab study only

How does Semaglutide work?

Semaglutide copies GLP-1, a gut hormone your body releases when you eat. It binds the GLP-1 receptor and switches it on. At the pancreas, it raises insulin and holds back glucagon, but only when blood sugar is high. It also slows how fast your stomach empties. GLP-1 receptors sit in brain regions that set appetite, so hunger signals fall too. A fatty acid chain sticks the drug to albumin in your blood, which is why it lasts. Semaglutide pulls one lever. Everything it does runs through that single receptor.

Educational reference only. Talk to a licensed clinician for any decisions on Semaglutide.

What are the side effects of Semaglutide?

EffectHow seriousWhat to watch
Nausea and diarrhea. These were the most common complaints in the main obesity trial, and they usually settled with time.[1]Common, usually mild to moderateNausea, vomiting and diarrhea, and whether you can still eat and drink normally
Side effects bad enough to stop treatment. In the large heart trial, roughly twice as many people quit semaglutide as quit placebo.[2]CommonWhether symptoms are settling over weeks or getting worse
Gallstones and gallbladder inflammation. A review of 76 randomised trials found a raised risk across this drug class.[9]Uncommon but seriousPain in the upper right belly, especially after meals, plus fever or yellowing skin
Worsening diabetic eye disease. In the type 2 diabetes heart trial, retinopathy complications were significantly more common on semaglutide.[3]Uncommon, serious in people who already have retinopathyAny change in vision. Tell your eye doctor before you start.
Weight regain after stopping. In the trial extension, most of the lost weight came back within a year of treatment ending.[8]Expected, not a toxicityWeight, blood pressure and blood sugar in the months after stopping

Is Semaglutide legal in 2026?

Checked 6 August 2026. Semaglutide is an approved prescription medicine in the United States, not a research chemical. FDA has approved it as Ozempic and Rybelsus for type 2 diabetes. It is also approved as Wegovy for weight management, and to cut cardiovascular risk in adults with heart disease and obesity or overweight. FDA's page on unapproved GLP-1 drugs is current as of 15 June 2026. It states that compounded versions are not FDA approved, and are not reviewed for safety, effectiveness or quality. It adds that salt forms, such as semaglutide sodium and semaglutide acetate, are different active ingredients from the approved drug. FDA says it is not aware of any lawful basis for using them in compounding. Products sold as 'for research purposes' or 'not for human consumption' have drawn FDA warning letters.

Status checked against the primary source.

Educational reference only. Talk to a licensed clinician for any decisions on Semaglutide.

If you are considering Semaglutide

This page does not provide dosing, cycling, stacking, or sourcing guidance for Semaglutide. The protocol conversation belongs with a licensed clinician who can review your bloodwork, history, and goals.

Where to buy Semaglutide

Running Semaglutide in your next protocol cycle?

Check out our recommended sources list to find vetted vendors you can trust.

View sources

Frequently Asked Questions

What does semaglutide actually do in the body?
It copies a gut hormone called GLP-1. That hormone does three useful things at once. It nudges the pancreas to release insulin when blood sugar rises. It slows how fast the stomach empties, so food sits longer. And it acts on appetite centres in the brain, so hunger drops and meals end sooner. Animal work confirms the brain part directly. The net result is lower blood sugar and less food eaten.
What did the main obesity trial actually show?
It enrolled 1961 adults with overweight or obesity, and without diabetes. They took semaglutide or placebo for 68 weeks, alongside lifestyle support. Average body weight fell by about 15 percent on the drug, against about 2 percent on placebo. Around half the semaglutide group lost 15 percent or more of their starting weight. That was a larger effect than any earlier weight drug had shown at that scale. Individual results varied a lot.
Does it actually protect the heart?
Yes, in the groups that were studied. One trial enrolled over 17,000 adults with existing heart disease and obesity but no diabetes. Cardiovascular death, heart attack or stroke happened in 6.5 percent on semaglutide, against 8.0 percent on placebo. An earlier trial in people with type 2 diabetes at high risk found a similar drop. Neither trial studied healthy people at normal weight, so the benefit is unproven there.
What happens if I stop taking it?
The weight comes back. In an extension of the main obesity trial, people were followed for a year after treatment stopped. They regained about two thirds of the weight they had lost. Blood pressure, blood fats and other markers drifted back toward where they started. The authors concluded that obesity behaves like a chronic condition, and that ongoing treatment is needed to hold on to the gains.
What are the real risks?
Gut symptoms are by far the most common. Nausea, vomiting and diarrhea hit a large share of users, mostly early on. In the big heart trial, 16.6 percent stopped the drug for side effects, against 8.2 percent on placebo. Gallstones and gallbladder inflammation are less common but serious. People with type 2 diabetes and existing eye damage had more retinopathy complications in one trial. The approved label also carries a boxed warning about thyroid tumors seen in rodents.
What should I ask a doctor before starting?
Ask whether you match the groups the trials actually studied. Ask about your personal and family history of medullary thyroid cancer, since the label rules that out. Mention any history of pancreatitis, gallstones or diabetic eye disease. Ask what monitoring you will get, and how long you would expect to stay on treatment. Then ask what the plan is if you stop, given the weight regain data.

References

  1. 1.Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. PMID: 33567185. DOI: 10.1056/NEJMoa2032183.
  2. 2.Lincoff AM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England journal of medicine. PMID: 37952131. DOI: 10.1056/NEJMoa2307563.
  3. 3.Marso SP, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England journal of medicine. PMID: 27633186. DOI: 10.1056/NEJMoa1607141.
  4. 4.Perkovic V, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. The New England journal of medicine. PMID: 38785209. DOI: 10.1056/NEJMoa2403347.
  5. 5.Kosiborod MN, et al. (2024). Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. PMID: 37952180. DOI: 10.1161/CIRCULATIONAHA.123.067505.
  6. 6.Pratley RE, et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology. PMID: 29397376. DOI: 10.1016/S2213-8587(18)30024-X.
  7. 7.Bliddal H, et al. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England journal of medicine. PMID: 39476339. DOI: 10.1056/NEJMoa2403664.
  8. 8.Wilding JPH, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, obesity & metabolism. PMID: 35441470. DOI: 10.1111/dom.14725.
  9. 9.He L, et al. (2022). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA internal medicine. PMID: 35344001. DOI: 10.1001/jamainternmed.2022.0338.
  10. 10.Gabery S, et al. (2020). Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. PMID: 32213703. DOI: 10.1172/jci.insight.133429.

One more time, because it matters

This page exists to identify Semaglutide and explain what the research describes. Underground Biohacking does not advise on dosage, cycling, stacking, or where to source prescription compounds. If Semaglutide is part of your plan, that conversation belongs with a clinician who can review your labs, history, and goals. Not with a website.